Mirum Pharmaceuticals, Inc.
Every calculator, already run for MIRM
Open the full toolkit →You have the numbers on MIRM. Get the argument.
A written report on which of these readings actually decide the outcome for Mirum Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering MIRMAnalyst Price Target Disagreement for Mirum Pharmaceuticals, Inc.
Wall Street's bull case implies +150% from the current price; the bear case implies +47%. A 102% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MIRM
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of p…
MIRM — frequently asked
Is MIRM a buy right now?
Wall Street's consensus rating on Mirum Pharmaceuticals, Inc. is Strong Buy across 14 analysts, with a mean price target of $153.07 (+91% vs. the current $80.14). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is MIRM overvalued?
MIRM trades at — trailing earnings, against a DCF fair value of $36 per share. The current price implies 16% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is MIRM's next earnings date?
Mirum Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 4, 2026. A full MIRM research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Mirum Pharmaceuticals, Inc.?
Analysts covering Mirum Pharmaceuticals, Inc. (MIRM) range from a bear-case target of $118.00 to a bull-case high of $200.00, with a mean consensus target of $153.07 across 14 analysts. The spread of $82.00 (102% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Mirum Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Mirum Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MIRM research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Mirum Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.